Apexigen raises $20m for CD40-targeting immunotherapy

Apexigen raised $20 million in a Series A1 funding round to finance development of APX005, a CD40 agonist and immunotherapeutic candidate.

Apexigen raised $20 million in a Series A1 funding round to finance development of APX005, a CD40 agonist and immunotherapeutic candidate.

Company

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category